BioCardia CEO Peter Altman buys 5,000 shares at depressed valuation amid company's sharp stock decline and ongoing losses.
Peter Altman, BioCardia's President and CEO, purchased 5,000 shares at a time when the stock is trading sharply below its highs following a steep recent decline. This is a meaningful signal of insider conviction—the company's CEO is putting his own capital at risk despite the stock's weakness and the company's fundamental challenges of unprofitable operations and contracting revenue. The trade is particularly noteworthy because Altman is buying into fundamental headwinds (the company remains deeply unprofitable with declining revenue trends), suggesting he believes the current depressed valuation offers a compelling entry point. For a CEO to accumulate shares in a loss-making biotech company during a downturn signals either that he sees a near-term catalyst or views the current price as a substantial discount to intrinsic value—both worth investigating further.